Stay up-to-date on new clinical findings in Oncoderm.
Oncoderm Editorials
Eruptive Squamous Cell Carcinomas Following Treatment With Fludarabine and Discussion of Treatment
Shah M, Wald J, Hanke CW. Eruptive Squamous cell carcinomas following treatment with fludarabine and discussion of treatment. J Drugs Dermatol. 2023;22(5):509-510.
Dilute Intralesional 5-Fluorouracil for the Treatment of Squamous Cell Carcinomas and Keratoacanthomas: A Case Series
Background: Intralesional 5-fluorouracil (5-FU) is a promising, yet sparsely studied alternative to surgical treatment for nonmelanoma skin cancer (NMSC).1 Previous studies of intralesional 5-FU have reported concentrations ranging from 30 to 50 mg/mL. To the best of our knowledge, this case series represents the first reported use of intralesional 5-FU 10.0 mg/mL and 16.7 mg/mL for NMSC.
The Prevalence of Sunscreen Use: A Cohort Study
Skin cancer is the most commonly diagnosed malignancy worldwide and continues to grow as a major public health concern. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), collectively referred to as nonmelanoma skin cancer (NMSC) or keratinocyte carcinomas, demonstrate an annual incidence that exceeds all other malignancies combined...
Advertisement
Podcasts
Saving Skin, Hair & Nails with Supportive Oncodermatology: A Call to Action for All Those Involved
While the old adage, “more oncology treatments, more skin problems,” becomes more like dogma every day with each new life saving therapy, fear not my friends, help is out there. Joining JDD podcast host Dr. Adam Friedman again, the man, the myth, the supportive oncodermatology legend, Dr. Mario Lacouture shares the latest guidance on managing these hair, skin and nail toxicities that are often considered by the patient even worse then the cancer these drugs treat. Get your support on – your patients will thank you.
This podcast series is supported by La Roche-Posay.
Supplements
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm
An increasing number of patients survive or are living with cancer. Anticancer treatments frequently have cutaneous adverse events (cAEs) that may severely impact patients’ quality of life and interrupt anticancer treatment. The US Cutaneous Oncodermatology Management (USCOM) project aims to improve cancer patients’ and survivors’ quality of life by offering tools for preventing and managing cAEs.
Read More
